Stockscreener 앱 받기
35.63
0.11%
0.04
시간 외 거래:
35.50
-0.13
-0.36%
전일 마감가:
$35.59
열려 있는:
$35.86
하루 거래량:
3.78M
Relative Volume:
2.57
시가총액:
$5.63B
수익:
$803.07M
순이익/손실:
$-358.81M
주가수익비율:
-12.41
EPS:
-2.87
순현금흐름:
$-374.21M
1주 성능:
-2.68%
1개월 성능:
+0.65%
6개월 성능:
-12.69%
1년 성능:
-26.28%
1일 변동 폭
$35.05
$36.40
1주일 범위
$35.05
$38.90
52주 변동 폭
$33.33
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
35.63 | 5.63B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Ionis gets FDA approval for Tryngolza - MSN
Ionis notches Arrowhead win; Tryngolza cleared for FCS - BioWorld Online
Ionis To Get Head Start On Arrowhead With Tryngzola Launch - Citeline News & Insights
Ionis gets a milestone approval; Another top FDA official to step down - BioPharma Dive
FDA approves Ionis’ TRYNGOLZA for FCS treatment - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Outperform" Rating from William Blair - MarketBeat
FDA approves Ionis’ Tryngolza - The Pharma Letter
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Yahoo Finance UK
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome - BioSpace
Ionis stock rises following FDA approval of TRYNGOLZA By Investing.com - Investing.com Canada
Ionis stock rises following FDA approval of TRYNGOLZA - Investing.com
FDA Approves Ionis Pharmaceuticals' (IONS) First Fully Owned Dru - GuruFocus.com
Olezarsen Earns First-Ever FDA Approval for Familial Chylomicronemia Syndrome - MD Magazine
Ionis Secures Historic FDA Approval for First-Ever FCS Treatment, TRYNGOLZA Shows 57% Triglyceride Reduction - StockTitan
US FDA approves Ionis Pharma's genetic disorder drug - Reuters
Ionis wins FDA approval for a rare disease therapy that lowers triglycerides - STAT
Ionis to hold third quarter 2024 financial results webcast - The Eastern Progress Online
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Geode Capital Management LLC Increases Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Update - MarketBeat
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Ionis Pharmaceuticals, Inc. announced that it expects to receive $624.972654 million in funding from Biogen Inc. - Marketscreener.com
Trend Tracker for (IONS) - Stock Traders Daily
Y Intercept Hong Kong Ltd Acquires Shares of 20,141 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Stifel Financial Corp - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CMS Tells MA Plans Not To Exclude Biogen’s Qalsody Because Of Accelerated Approval - Citeline
XTX Topco Ltd Takes $673,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% - MSN
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Ionis to present at upcoming investor conferences - Longview News-Journal
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year By Investing.com - Investing.com Nigeria
Transthyretin Amyloid Cardiomyopathy Market: Size, Share, - openPR
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease - The Eastern Progress Online
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Groupama Asset Managment - MarketBeat
Ionis announces proposed public offering of common stock - The Eastern Progress Online
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More - BioSpace
Narrow-Moat Ionis Is Expanding Its Neurology and Cardiology Portfolio to Strengthen Its Moat - Morningstar
Ionis announces pricing of $500.3 million public offering - The Eastern Progress Online
Ionis Pharmaceuticals : announces appointment of Brett P. Monia Ph.D. to its board of directors - Marketscreener.com
Ionis Pharmaceuticals : to Provide Corporate Update at 2019 Annual Meeting of Stockholders - Marketscreener.com
Ionis Pharmaceuticals : Provides Corporate Update at 2018 Annual Meeting of Stockholders - Marketscreener.com
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Company plans to seek Canada OK of HAE treatment donidalorsen - Angioedema News Today
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Nov 12 '24 |
Sale |
38.05 |
6,630 |
252,294 |
167,393 |
| LOSCALZO JOSEPH | Director |
Nov 12 '24 |
Sale |
37.86 |
13,508 |
511,426 |
32,251 |
2.88%
2.65%
자본화:
|
볼륨(24시간):